Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sex Discrepancies in OAT Effect on Incident HCV

Clin Infect Dis; ePub 2019 Feb 28; Geddes, et al

Female people who inject drugs (PWID) exposed to opioid agonist therapy (OAT) are twice as likely to acquire hepatitis C virus (HCV) infection than their male counterparts, a new study found. Researchers assessed sex disparities in HCV incidence among PWID exposed to OAT and factors independently associated with decreased protective efficacy. They found:

  • HCV incidence was 16.5 person-years observation (PYO) in females and 7.6 PYO in males among 701 participants exposed to OAT over 3,003 visits and 1,427 PYO.
  • Factors associated with HCV acquisition among females exposed to OAT included nonwhite race, recent unstable housing, recent daily or more frequent injection, and recent receptive syringe sharing.
  • Interventions that target women are required to bolster the efficacy of OAT in preventing HCV transmission.

Citation:

Geddes L, Iversen J, Wand H, et al. Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection. [Published online ahead of print February 28, 2019]. Clin Infect Dis. doi:10.1093/cid/ciz162.